Uppsala, Sweden, Oct. 24, 2016 (GLOBE NEWSWIRE) -- As previously announced on October 24 2016 Oasmia has acquired a novel cancer project which was paid for by 3,080,000 newly issued shares at a share price of approximately SEK 8.12 per share
In order to enable the transaction, the Board of Directors of Oasmia has, pursuant to the authorization granted by the annual general meeting held on September 26, 2016, resolved on a directed issue of 3,080,000 new shares.
Through the issue, the number of shares in Oasmia increases by 3,080,000 from 115,959,310 to 119,039,310 and the share capital increases by SEK 308,000 from SEK 11,595,931 to SEK 11,903,931. The new issue results in an equity dilution of approximately 2.6 percent after the issue is completed.
The information above has been made public in accordance with the Securities Market Act and the Financial Instruments Trading Act.
Notes to editors:
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company's product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm (OASM.ST).
Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the constituent information in accordance with the rules and regulations prevailing in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Oasmia Pharmaceutical AB (publ) securities in any jurisdiction, neither from Oasmia Pharmaceutical AB (publ) nor anyone else.
Tel: +46 18 50 54 40
Source: Oasmia Pharmaceutical